相关实验视频
Updated: Jan 17, 2026

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.6K
基于血小板特异性的新型血小板类PLGA-PSP纳米颗粒缓解创伤性出血
Wenda Fu1, Hua Wei1, Dongxia Ren1
1Department of Transfusion Medicine, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710038, People's Republic of China.
International journal of nanomedicine
|September 25, 2025
概括
研究人员开发了新的类似血小板的纳米粒子 (PLGA-PSP),以应对血小板缩物供应的挑战. 这些安全有效的纳米粒子在创伤性出血中显示出快速血液静止的前景.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 血液静止研究 血液静止研究
背景情况:
- 血小板对于凝血至关重要,但供应短缺带来了临床挑战.
- 创伤性出血需要有效和安全的血小板替代品.
- 目前血小板度的限制促使人们寻找替代品.
研究的目的:
- 为了合成和评估新的血小板样纳米颗粒 (PLGA-PSP) 作为血小板缩物的替代品.
- 评估PLGA-PSP纳米颗粒的生物安全性和静血疗效.
- 研究PLGA-PSP纳米颗粒在治疗创伤性出血方面的潜力.
主要方法:
- 通过将血小板特异性与PLGA-PEG纳米粒子结合,合成了PLGA-PSP纳米粒子.
- 评估了纳米粒子生物安全性和体外对血小板粘附,聚合和激活的影响.
- 在尾脉,肝脏和大腿动脉出血的小鼠模型中评估了静血疗效.
主要成果:
- 成功合成了具有特定静血能力的无毒PLGA-PSP纳米颗粒.
- 证明显著诱导血小板粘附和聚合,没有不良激活.
- 在各种出血模型中有效减少出血时间和血液损失.
结论:
- PLGA-PSP纳米颗粒为快速静血提供了一个有前途的治疗策略.
- 开发的纳米颗粒显示出对创伤性出血的生物安全性和有效性.
- 这种新的方法可以克服与传统血小板输血相关的局限性.
相关概念视频
Formation of the Platelet Plug
8.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.7K
Introduction to Hemostasis
13.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
13.4K
Structure and Function of Platelets
3.0K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
3.0K
Clot Retraction and Fibrinolysis
8.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K

